Patented Probiotic Microencapsulation Technology Opens New Markets for Vésale Pharma

9 Sep 2013 --- After having opened the European market, the Belgian pharmaceutical company Vésale Pharma has now signed major distribution contracts in China and in the Middle-East area.

These agreements focus on the new worldwide probiotic patent INTELICAPS, developed in January 2011.

INTELICAPS offers new performances to probiotics by a strongly increased protection and a prolonged viability, even under extreme conditions.

With these new agreements, Vésale Pharma will keep on addressing new challenges and opening up new perspectives to the worldwide market of probiotic-based products.
 
A major distribution contract has been signed in June 2013 with a leading pediatric drugs company in China: Hainan Honz Pharmaceutical Co. Ltd.

A publicly traded company, Hainan Honz Pharmaceutical Co. Ltd. is listed on the Shenzhen Stock Exchange with headquarters in Guangzhou. Hainan Honz is principally engaged in the research, development, production, and distribution of a wide range of pediatric drugs for children in China.

This agreement will cover the distribution of all the child-focused probiotic products of the Vésale portfolio in China.

“This agreement shows that we are indeed innovative in the field of probiotics. It is a further recognition of Vésale Pharma’s leading position in delivering Probiotic Solutions for all life stage,” says the company's International Director Johan Quintens.

Hainan Honz also considers this agreement an opportunity. “Our distribution agreement with Vésale Pharma draws on the strengths of both our companies, creating a strong, strategic partnership for the development, registration, distribution, and sales of Vésale’s probiotic portfolio. The localization of the INTELICAPS probiotic line for the Chinese market is the first time Honz has brought in leading edge international probiotic technologies and products to enhance our children’s health product lineup,” confirms Honz’s Marketing Director Bin Xiao.
 
At the same time, Vésale Pharma is starting commercialization of a Probiotic range in the Middle-East market.
The company has contracted distributors and obtained first market authorizations for the United Arabs Emirates and for Kuwait. First in-market sales have just started, and additional markets will follow soon.

Over the last few years, the Middle-East has experienced an increased demand for scientifically documented and quality probiotics.
 
These new developments offer strategic opportunities to the company which are expected to generate multi-million sales in the years to come.
 
Developed in January 2011, INTELICAPS is an innovative stabilisation procedure for probiotics. It consists of a technology for embedding the probiotics in a stabilising and nourishing matrix made of microspheres. At the same time, due to layer-by-layer coating, the probiotics are protected against environmental impacts and benefit from long-lasting stabilisation. The microcapsules also resist low pH levels, making it possible for them to pass through the stomach without opening and deliver 100 to 1000 times more viable probiotics directly to the intestine.